About Careers Internship MedBlog Contact us
Medindia LOGIN REGISTER
Advertisement

Understanding the Cellular Mechanisms in Rheumatoid Arthritis

by Dr. Trupti Shirole on November 15, 2016 at 3:38 PM
Font : A-A+

 Understanding the Cellular Mechanisms in Rheumatoid Arthritis

Rheumatoid arthritis (RA) is a chronic disease that causes pain, stiffness, swelling, and limitation in the motion and function of multiple joints. Though joints are the principal body parts affected by RA, inflammation can develop in other organs as well. An estimated 1.3 million Americans have RA, and the disease typically affects women twice as often as men.

Early diagnosis and initiation of effective therapy is an important strategy in RA management. Researchers at the Mayo Clinic in Rochester, Minn., drew on their recent findings that showed that RA patients' pre-treatment serum type-1 interferon (IFN)-β/α ratio could predict their response to tumor necrosis factor-alpha inhibitors (TNFi). They conducted a new study to look for the cellular mechanisms involved in this response.

Advertisement


Distinct gene expression signatures in rheumatoid arthritis patients could help rheumatologists predict how these individuals will respond to tumor necrosis factor inhibitors, and may one day enable a more personalized approach to RA therapy, revealed new research findings presented this week at the 2016 ACR/ARHP Annual Meeting in Washington.

"The aim of this study was to better understand the impact of the type-I interferon ratio that predicts non-response to TNFi therapy on a major inflammatory cell type involved in RA," said Theresa L. Wampler Muskardin,a rheumatologist in the Department of Pediatric and Adolescent Medicine, and a lead author of the study. "Effects of type-I interferon on single cells and immune cell subtypes may be missed when we analyze whole blood or mixed cell populations. Using single cell gene expression technology, we hoped to find differences in expression of select genes between treatment responders and non-responders, which could ultimately lead to a blood test that we can use to guide treatment decisions in RA patients prior to starting biologic therapy."
Advertisement

The researchers used single cell expression analysis to study whether monocyte gene expression was significantly different among RA patients based on their pre-treatment blood serum IFN- β/α ratio. They isolated single classical (CL) and single non-classical (NC) blood-derived monocytes from 15 seropositive RA patients before TNFi therapy. The patients were divided into two groups according to their pre-TNFi serum ratio: six patients in IFN-β/α>1.3 and nine patients in IFN-β/α<1.3. The researchers performed unsupervised hierarchical clustering of 87 target genes on the single monocytes.

Results of the testing showed that JAK1 and IL1A strongly differentiated between the two groups. In NC cells only, expression of STAT2, ILT7, PKR, TLR7 and IRAK1 were more likely in the non-response patient group. In CL cells only, expression of IFIT2 and CD36 was more likely. In a multivariate logistic regression, IL1A, CD32a, IL-8, TYK2 and IRAK1 in NC plus CL monocytes aligned with the treatment response groups. In comparison with that mixed monocyte model, IL-8 and IRAK1 in NC, and CXCR3 in CL showed even stronger alignment with the treatment response groups. STAT2 strongly predicted the response group in NC cells alone. CXCL9 strongly predicted the response group in CL cells alone.

Their previous work showed that an IFN- β/α ratio>1.3 is predictive of non-response to anti-TNF therapy in RA patients. In this study, their findings show that gene expression in monocyte subsets differ in RA patients who have an IFN-β/α ratio>1.3, the ratio of type-I IFNs that predicts non-response to anti-TNF therapy.

"Difference between therapy response groups was strongest when the monocyte subsets were analyzed separately, rather than together, and distinct expression signatures were identified in the subsets," said Dr. Muskardin. "This suggests that investigating these biological pathways in monocyte subsets will provide further insight into the biology that determines TNFi treatment response in RA, and may identify other targets for therapy or other markers predictive of TNFi response that may be easier to measure."

Future studies should focus on monocyte subsets to identify possible molecular differences that could also determine treatment response to TNFi biologics. In the future, rheumatologists may be able to tailor therapy to an RA patient based on his or her underlying disease biology, Dr. Muskardin concluded.

Source: Eurekalert
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
What's New on Medindia
Alarming Cesarean Section Trends in India - Convenience or Compulsion of Corporate Healthcare
Quiz on Low-Calorie Diet for Diabetes
World Heart Day in 2022- Use Heart for Every Heart
View all
Recommended Reading
News Archive
Date
Category
Advertisement
News Category

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Osteoarthritis Rheumatoid Arthritis Oligoarthritis Spondylolisthesis Chemotherapy Chemotherapy Drugs Knee Replacement Hypermobility Syndrome Autoimmune Disorders Arthritis 

Most Popular on Medindia

Loram (2 mg) (Lorazepam) Vent Forte (Theophylline) Blood - Sugar Chart Nutam (400mg) (Piracetam) Indian Medical Journals The Essence of Yoga Find a Doctor Hearing Loss Calculator Iron Intake Calculator Drug Side Effects Calculator
This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use
×

Understanding the Cellular Mechanisms in Rheumatoid Arthritis Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests